Cases of 2019-nCoV have now been identified in 18 countries


  • Heather Mason
  • Univadis Medical News
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

2019 n-CoV is evolving rapidly as the number of cases continues to rise. Outside of China, the geographical range and the number of cases increases, governments are implementing travel restrictions, flights are being suspended and health care workers are advised to be vigilant.

Key Updates:

  • Confirmed cases 5,974, death toll 132 (all in China).
  • Cases are now reported in 18 countries.
  • European Centre for Disease Prevention and Control (ECDC) reports the first case in Germany.
  • A fourth case has been confirmed in France, and six in Australia.
  • Flights from many countries to mainland China have been suspended.
  • The WHO has launched a Global Clinical Data Platform to allow member states to share anonymised clinical data.
  • The source of infection remains unknown and could still be active.
  • A randomised controlled trial of the anti-HIV drug combination of lopinavir and ritonavir has been started in Wuhan. 

Patients with 2019-nCoV infection are presenting with a wide range of symptoms. Most seem to have mild disease. About 20 per cent appear to progress to severe disease, including pneumonia, respiratory failure and in some cases death.

The organisation has developed interim clinical guidelines for the management of hospitalised patients and for mildly ill patients at home.